Beijing Pearl Biotechnology Limited Liability Company

This study is testing whether adding a new oral drug called vebreltinib to standard chemotherapy works better than chemotherapy alone for people with advanced non-squamous non-small cell lung cancer (NSCLC) who have a specific genetic feature called MET-positive. The trial aims t…